Details for New Drug Application (NDA): 217873
✉ Email this page to a colleague
NDA 217873 describes SUCCINYLCHOLINE CHLORIDE, which is a drug marketed by Accord Hlthcare, Adaptis, Amneal, Amphastar Pharms Inc, Amring Pharms, Aspiro, Baxter Hlthcare Corp, Be Pharms, Breckenridge, Deva Holding As, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Intl Medication, Mankind Pharma, Meitheal, Micro Labs, Nexus, Organon Usa Inc, Sagent Pharms Inc, Somerset Theraps Llc, Umedica, Zydus Pharms, and Steriscience, and is included in twenty-eight NDAs. It is available from twenty-six suppliers. Additional details are available on the SUCCINYLCHOLINE CHLORIDE profile page.
The generic ingredient in SUCCINYLCHOLINE CHLORIDE is succinylcholine chloride. There are six drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the succinylcholine chloride profile page.
The generic ingredient in SUCCINYLCHOLINE CHLORIDE is succinylcholine chloride. There are six drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the succinylcholine chloride profile page.
Summary for 217873
| Tradename: | SUCCINYLCHOLINE CHLORIDE |
| Applicant: | Steriscience |
| Ingredient: | succinylcholine chloride |
| Patents: | 0 |
Pharmacology for NDA: 217873
| Physiological Effect | Neuromuscular Depolarizing Blockade |
Medical Subject Heading (MeSH) Categories for 217873
Suppliers and Packaging for NDA: 217873
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SUCCINYLCHOLINE CHLORIDE | succinylcholine chloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 217873 | ANDA | STERISCIENCE SPECIALTIES PRIVATE LIMITED | 82449-232 | 82449-232-02 | 10 SYRINGE in 1 PACKAGE (82449-232-02) / 5 mL in 1 SYRINGE (82449-232-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | Strength | 100MG/5ML (20MG/ML) | ||||
| Approval Date: | Jul 9, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
